Cover Image
Market Research Report

Hospital Acquired Pneumonia (HAP) - Pipeline Review, H1 2019

Published by Global Markets Direct Product code 271831
Published Content info 161 Pages
Delivery time: 1-2 business days
Price
Back to Top
Hospital Acquired Pneumonia (HAP) - Pipeline Review, H1 2019
Published: February 1, 2019 Content info: 161 Pages
Description

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hospital Acquired Pneumonia (HAP) - Pipeline Review, H1 2019, provides an overview of the Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline landscape.

Hospital Acquired Pneumonia (HAP) is defined as pneumonia acquired during hospital stay. Symptoms include cough, fever, shaking chills, confusion, headache and loss of appetite. Risk factors include chronic lung disease, cigarette smoking, dementia, stroke, brain injury, heart disease, liver cirrhosis and diabetes mellitus. Treatment includes antibiotics and healthy lifestyle.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hospital Acquired Pneumonia (HAP) - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Hospital Acquired Pneumonia (HAP) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hospital Acquired Pneumonia (HAP) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 8, 5, 10, 10, 2 and 1 respectively.

Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hospital Acquired Pneumonia (HAP) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Hospital Acquired Pneumonia (HAP) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hospital Acquired Pneumonia (HAP) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hospital Acquired Pneumonia (HAP) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hospital Acquired Pneumonia (HAP) (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hospital Acquired Pneumonia (HAP) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Product Code: GMDHC11081IDB

Table of Contents

  • Introduction
  • Hospital Acquired Pneumonia (HAP) - Overview
  • Hospital Acquired Pneumonia (HAP) - Therapeutics Development
  • Hospital Acquired Pneumonia (HAP) - Therapeutics Assessment
  • Hospital Acquired Pneumonia (HAP) - Companies Involved in Therapeutics Development
  • Hospital Acquired Pneumonia (HAP) - Drug Profiles
  • Hospital Acquired Pneumonia (HAP) - Dormant Projects
  • Hospital Acquired Pneumonia (HAP) - Discontinued Products
  • Hospital Acquired Pneumonia (HAP) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Hospital Acquired Pneumonia (HAP), H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products under Development by Companies, H1 2019 (Contd..1), H1 2019
  • Products under Development by Companies, H1 2019
  • Products under Development by Companies, H1 2019 (Contd..1), H1 2019
  • Products under Development by Companies, H1 2019 (Contd..2), H1 2019
  • Products under Development by Companies, H1 2019 (Contd..3), H1 2019
  • Number of Products by Stage and Target, H1 2019
  • Number of Products by Stage and Mechanism of Action, H1 2019
  • Number of Products by Stage and Route of Administration, H1 2019
  • Number of Products by Stage and Molecule Type, H1 2019
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Aridis Pharmaceuticals Inc, H1 2019
  • Hospital Acquired Pneumonia (HAP) - Pipeline by AstraZeneca Plc, H1 2019
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Centauri Therapeutics Ltd, H1 2019
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Cumberland Pharmaceuticals Inc, H1 2019
  • Hospital Acquired Pneumonia (HAP) - Pipeline by CytaCoat AB, H1 2019
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Destiny Pharma Plc, H1 2019
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2019
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Evaxion Biotech ApS, H1 2019
  • Hospital Acquired Pneumonia (HAP) - Pipeline by MedImmune LLC, H1 2019
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Meiji Seika Pharma Co Ltd, H1 2019
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Merck & Co Inc, H1 2019
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Motif Bio Plc, H1 2019
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Nabriva Therapeutics Plc, H1 2019
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Polyphor AG, H1 2019
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Sealife PHARMA GMBH, H1 2019
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Shionogi & Co Ltd, H1 2019
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Spero Therapeutics Inc, H1 2019
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Tetraphase Pharmaceuticals Inc, H1 2019
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Wockhardt Ltd, H1 2019
  • Hospital Acquired Pneumonia (HAP) - Dormant Projects, H1 2019
  • Hospital Acquired Pneumonia (HAP) - Dormant Projects, H1 2019 (Contd..1), H1 2019
  • Hospital Acquired Pneumonia (HAP) - Discontinued Products, H1 2019

List of Figures

  • Number of Products under Development for Hospital Acquired Pneumonia (HAP), H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products by Top 10 Targets, H1 2019
  • Number of Products by Stage and Top 10 Targets, H1 2019
  • Number of Products by Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Routes of Administration, H1 2019
  • Number of Products by Stage and Routes of Administration, H1 2019
  • Number of Products by Molecule Types, H1 2019
  • Number of Products by Stage and Molecule Types, H1 2019
Back to Top